Inhaled antibiotics are a form of treatment for respiratory infections, particularly in patients with chronic lung diseases such as cystic fibrosis and bronchiectasis. These antibiotics are delivered directly to the lungs through inhalation, allowing for higher concentrations at the site of infection while minimizing systemic side effects. Inhaled antibiotics can help reduce bacterial colonization in the lungs, improve lung function, and decrease the frequency of exacerbations in patients with chronic respiratory conditions. They are often used in combination with other therapies such as airway clearance techniques and oral antibiotics. Commonly used inhaled antibiotics include tobramycin, colistin, and aztreonam, and the delivery can be through nebulizers, inhalers, or dry powder devices. Research in this field focuses on optimizing drug delivery mechanisms, improving efficacy and safety of inhaled antibiotics, and identifying new compounds for treatment of respiratory infections.